Samsung Biologics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Samsung Biologics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 23 Dec 2022 | Lorem |
| LoA Update: Samsung Bioepis’ Soliris biosimilar approval likelihood in PNH rises by 27 points after Phase III completion | 29 Oct 2021 | Reynald Castaneda |
| Biosimilar interchangeability studies to have limited benefit on US uptake without shifts in legal framework and patient, physician and payer education, experts say | 30 May 2018 | Shuan Sim |
| Rituximab biosimilars in Europe likely to see widespread RA uptake; originator preferred in some NHL settings – experts | 22 Apr 2016 | Alaric DeArment, Alissa Fleck |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer